Clonidine extended-release tablets for the treatment of ADHD. (April 2012)

• Record Type: Journal Article
• Authors: Daughton, Joan; Corr, Lindsey; Liu, Howard; West, Madeline
• Is Part Of: Neuropsychiatry. Volume 2:Number 2(2012)
• Page Start: 117
• Page End: 123
• Publication Date: 2012-04
• Subjects: Psychology, Pathological -- Periodicals; Mental illness -- Periodicals; Neuropsychiatry -- Periodicals; Mental Disorders -- Periodicals; Nervous System Diseases -- Periodicals; Neuropsychiatry -- Periodicals; Mental illness; Neuropsychiatry; Psychology, Pathological; 616.8
• DOI: 10.2217/npy.12.7
• Languages: English
• ISSNs: 1758-2008

Abstract

SUMMARY Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.